ATE407120T1 - 3-((hetero)arylsulfonyl)-8- ä(aminoalkyl)oxyüchinoline als antagonisten des 5-ht6-rezeptors zur behandlung von erkrankungen des zns - Google Patents
3-((hetero)arylsulfonyl)-8- ä(aminoalkyl)oxyüchinoline als antagonisten des 5-ht6-rezeptors zur behandlung von erkrankungen des znsInfo
- Publication number
- ATE407120T1 ATE407120T1 AT05729157T AT05729157T ATE407120T1 AT E407120 T1 ATE407120 T1 AT E407120T1 AT 05729157 T AT05729157 T AT 05729157T AT 05729157 T AT05729157 T AT 05729157T AT E407120 T1 ATE407120 T1 AT E407120T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- oxyquinolines
- arylsulfonyl
- aminoalkyl
- hetero
- Prior art date
Links
- 108091005435 5-HT6 receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0407025.6A GB0407025D0 (en) | 2004-03-29 | 2004-03-29 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE407120T1 true ATE407120T1 (de) | 2008-09-15 |
Family
ID=32188902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05729157T ATE407120T1 (de) | 2004-03-29 | 2005-03-24 | 3-((hetero)arylsulfonyl)-8- ä(aminoalkyl)oxyüchinoline als antagonisten des 5-ht6-rezeptors zur behandlung von erkrankungen des zns |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20070191345A1 (de) |
| EP (1) | EP1730112B1 (de) |
| JP (1) | JP2007530648A (de) |
| AT (1) | ATE407120T1 (de) |
| DE (1) | DE602005009512D1 (de) |
| ES (1) | ES2313319T3 (de) |
| GB (1) | GB0407025D0 (de) |
| WO (1) | WO2005095346A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2309154C9 (ru) * | 2002-03-27 | 2016-09-27 | Глэксо Груп Лимитед | 3-фенилсульфонил-8-пиперазин-1-ил-хинолины, обладающие аффинностью к 5-нт6 рецептору, способы их получения (варианты) |
| DE602004000260T2 (de) | 2003-07-22 | 2006-08-24 | Arena Pharmaceuticals, Inc., San Diego | Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen |
| GB0519758D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel process |
| US20100041672A1 (en) * | 2007-03-21 | 2010-02-18 | Glaxo Group Limited | Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome |
| PE20090595A1 (es) | 2007-08-15 | 2009-06-06 | Glaxo Group Ltd | Derivados de quinoliniloxipiperidina y pirrolidina como antagonistas del receptor h1 |
| EP2508177A1 (de) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Kombinationen mit 3-phenylsulfonyl-8-piperazinyl-1yl-chinolin |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| US10022355B2 (en) | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
| BR112018000728A2 (pt) | 2015-07-15 | 2018-09-04 | Axovant Sciences Gmbh | resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo |
| CN107698503A (zh) * | 2017-11-22 | 2018-02-16 | 金凯(辽宁)化工有限公司 | 一种8‑氟喹啉的制备方法和3‑碘‑8‑氟喹啉的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2244438T3 (es) * | 1999-05-24 | 2005-12-16 | Mitsubishi Pharma Corporation | Compuestos de fenoxipropilamina. |
| CN1800185A (zh) * | 2001-06-11 | 2006-07-12 | 比奥维特罗姆股份公司 | 取代的磺酰胺化合物、其制备方法及其作为治疗cns疾病、肥胖和ii型糖尿病的药物的应用 |
| WO2003080608A2 (en) * | 2002-03-27 | 2003-10-02 | Glaxo Group Limited | Quinoline and aza-indole derivatives and their use as 5-ht6 ligands |
| RU2309154C9 (ru) * | 2002-03-27 | 2016-09-27 | Глэксо Груп Лимитед | 3-фенилсульфонил-8-пиперазин-1-ил-хинолины, обладающие аффинностью к 5-нт6 рецептору, способы их получения (варианты) |
| WO2004000828A1 (en) * | 2002-06-20 | 2003-12-31 | Biovitrum Ab | New compounds useful for the treatment of obesity, type ii diabetes and cns disorders |
| GB0320320D0 (en) * | 2003-08-29 | 2003-10-01 | Glaxo Group Ltd | Novel compounds |
| GB0321473D0 (en) * | 2003-09-12 | 2003-10-15 | Glaxo Group Ltd | Novel compounds |
-
2004
- 2004-03-29 GB GBGB0407025.6A patent/GB0407025D0/en not_active Ceased
-
2005
- 2005-03-24 US US10/599,002 patent/US20070191345A1/en not_active Abandoned
- 2005-03-24 EP EP05729157A patent/EP1730112B1/de not_active Expired - Lifetime
- 2005-03-24 ES ES05729157T patent/ES2313319T3/es not_active Expired - Lifetime
- 2005-03-24 DE DE602005009512T patent/DE602005009512D1/de not_active Expired - Fee Related
- 2005-03-24 AT AT05729157T patent/ATE407120T1/de not_active IP Right Cessation
- 2005-03-24 WO PCT/GB2005/001106 patent/WO2005095346A1/en not_active Ceased
- 2005-03-24 JP JP2007505618A patent/JP2007530648A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20070191345A1 (en) | 2007-08-16 |
| EP1730112B1 (de) | 2008-09-03 |
| EP1730112A1 (de) | 2006-12-13 |
| GB0407025D0 (en) | 2004-04-28 |
| DE602005009512D1 (de) | 2008-10-16 |
| JP2007530648A (ja) | 2007-11-01 |
| ES2313319T3 (es) | 2009-03-01 |
| WO2005095346A1 (en) | 2005-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1716152T3 (pl) | Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych | |
| ATE517882T1 (de) | Chinolinderivate | |
| SE0303180D0 (sv) | Novel compounds | |
| SE0302232D0 (sv) | Novel Compounds | |
| SE0201635D0 (sv) | Novel compounds | |
| NO20063599L (no) | Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
| EA200500304A1 (ru) | Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний | |
| MXPA05011166A (es) | Antagonistas del receptor del peptido relacionado con el gen de la calcitonina. | |
| DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
| CY1111070T1 (el) | Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace) | |
| DE60038686D1 (de) | Oheptan-derivate und ihre verwendung als integrin-rezeptor-antagonisten | |
| NO20090979L (no) | (3-amino-1,2,3,4-tetrahydro-9H-karbazol-9-yl)-eddiksyrederivater | |
| EA200601239A1 (ru) | Замещённые хинолиновые соединения | |
| ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| NO20063821L (no) | Kinolinderivater for anvendelse som mykobakterielle inhibitorer | |
| MX2009003981A (es) | Agentes moduladores del receptor de calcio. | |
| ATE517861T1 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| MY147677A (en) | Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases | |
| MX2007007103A (es) | Derivados espiro como inhibidores de lipoxigenasa. | |
| EA200501595A1 (ru) | Азабициклические производные в качестве антагонистов мускаринового рецептора | |
| ATE407120T1 (de) | 3-((hetero)arylsulfonyl)-8- ä(aminoalkyl)oxyüchinoline als antagonisten des 5-ht6-rezeptors zur behandlung von erkrankungen des zns | |
| ATE512142T1 (de) | Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität | |
| ATE432278T1 (de) | Verbindungen zur behandlung von krankheiten | |
| MX2009005541A (es) | Indoles que actuan como antagonistas del receptor v1a. | |
| EA200501594A1 (ru) | Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |